11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists

A method of treating a mammal with an FP receptor related disorder selected from the group consisting of:

• ocular hyperemia, cystoid macular edema, iris hyperpigmentation, iris melanogenesis, acute and chronic inflammation, benign prostatic hypertrophy, uterine cramps, irritable bowel disease, cardiac arrythmias, epilepsy, excessive bone deposition, and premature labor, comprising administering to such mammal a therapeutically effective amount of a compound of formula I:.
• wherein:
• R1=CO2R, CONR4R5, CH2OR6, or CH2NR7R8;
• where:
• R=H or cationic salt moiety, or CO2R=pharmaceutically acceptable ester moiety;
• R4, R5=same or different=H or alkyl;
• R6=H, acyl, or alkyl;
• R7, R8=same or different=H, acyl, or alkyl;
• with the proviso that if one of R7, R8=acyl, then the other=H or alkyl;
• n=0 or 2;
• R2, R3=same or different=H, alkyl, or acyl;
• =single or non-cumulated double bond, with the provisos that if a double bond is present between carbons 4 and 5, it is of the cis configuration;
• and that if a double bond is present between carbons 13 and 14, it is of the trans configuration;
• X=(CH2)m or (CH2)mO, where m=1-6;
• and
• Y=phenyl, optionally substituted with alkyl, halo, trihalomethyl, alkoxy, acyl, acyloxy, amino, alkylamino, acylamino, or hydroxy;
• or
• X—Y=(CH2)pY1;
• where p=0-6;
• and
• wherein:
• W═CH2, O, S(O)q, NR10, CH2CH2, CH═CH, CH2O, CH2S(O)q, CH═N, or CH2NR9;
• where q=0-2, and R10=H, alkyl, or acyl;
• Z=H, alkyl, alkoxy, acyl, acyloxy, halo, trihalomethyl, amino, alkylamino, acylamino, or hydroxy;
• and
• =single or double bond.